Note: The full article and accompanying features are only available whilst being signed in.
Summary
The reasons for the Pharmaceutical Industry’s vulnerability are many, but one culprit is the increasing requirements to create medication. Researching and developing a commercial prescription drug today requires an average total investment of $500 Million and 10 - 15 years of lab work, clinical trials and extensive regulatory review. When the drug is finally out in the marketplace, it enjoys only a brief period of monopoly and profit before patent expiration and plummeting market share in the face of a Generic takeover.
The situation is grim. It can seem like Pharmaceutical Companies have no recourse in the face of the lower prices and operating costs of the Generics Industry and fortunes will only continue to fade. However, options do exist for Pharmaceutical Companies to mount an effective defense strategy against the threats posed by Generics. In this report, we examine some of these defensive strategies. We analyze the environment for Pharmaceuticals today, as well as the Generic Industry as a whole. We describe the pros and cons of legal defensive strategies as well as opportunities to expand the revenue-generating product life cycle into reformulations and over-the-counter medications.
We look at pricing strategies as well as company organizational changes as part of an integrated defense strategy and, to help companies make touch decisions about the best defense, we examine powerful analytics techniques and case studies.
To purchase this report, please visit:
> How to Plan an Effective Generics Defense Strategy
Want more?
The content of this page been summarized. To view the full content, please register or sign in to the Eularis web site.
Register with Eularis
or
Sign in